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Objectives This study determined whether greater volumes of exercise were associated with greater reductions in clinical
events.
Background The HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial showed that
among patients with heart failure (HF), regular exercise confers a modest reduction in the adjusted risk for all-
cause mortality or hospitalization.
Methods Patients randomized to the exercise training arm of HF-ACTION who were event-free at 3 months after random-
ization were included (n  959). Median follow-up was 28.2 months. Clinical endpoints were all-cause mortality
or hospitalization and cardiovascular mortality or HF hospitalization.
Results A reverse J-shaped association was observed between exercise volume and adjusted clinical risk. On the basis of Cox
regression, exercise volume was not a significant linear predictor but was a logarithmic predictor (p  0.03) for all-
cause mortality or hospitalization. For cardiovascular mortality or HF hospitalization, exercise volume was a significant
(p  0.001) linear and logarithmic predictor. Moderate exercise volumes of 3 to 5 metabolic equivalent (MET)-h and
5 to 7 MET-h per week were associated with reductions in subsequent risk that exceeded 30%. Exercise volume
was positively associated with the change in peak oxygen uptake at 3 months (r  0.10; p  0.005).
Conclusions In patients with chronic systolic HF, volume of exercise is associated with the risk for clinical events, with only
moderate levels (3 to 7 MET-h per week) of exercise needed to observe a clinical benefit. Although further study
is warranted to confirm the relationship between volume of exercise completed and clinical events, our findings
support the use of regular exercise in the management of these patients. (Heart Failure: A Controlled Trial Inves-
tigating Outcomes of Exercise Training [HF-ACTION]; NCT00047437) (J Am Coll Cardiol 2012;60:1899–905)
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Exercise Volume and Heart Failure November 6, 2012:1899–905Among patients with coronary
heart disease, cardiac rehabilita-
tion (CR) reduces the risk for
all-cause mortality and cardio-
vascular (CV) mortality approxi-
mately 20% and 25%, respec-
tively (1–3). Studies involving
exercise training in patients with
heart failure (HF) also demon-
strate a benefit on clinical events
(4–7). However, despite the im-
portant contribution that these
studies made toward the care of patients with CV disease,
the question remains as to the relation between the volume
of exercise completed and magnitude of reduction in risk for
experiencing a subsequent clinical event.
Suaya et al. (8) observed that the adjusted relative risk for
mortality was reduced almost 20% in patients with coronary
heart disease who attended 25 sessions of CR, versus
patients who attended 24 or fewer sessions. Similarly,
among Medicare beneficiaries with HF who attended 36
versus 12 CR sessions, all-cause mortality and myocardial
infarction were both reduced approximately 18% (9). Fi-
nally, Taylor et al. (2) dichotomized exercise dose on the
basis of patients completing more or less than 1,000 units of
exercise and reported no association between dose of exer-
cise and risk for clinical outcomes.
The HF-ACTION (Heart Failure: A Controlled Trial
Investigating Outcomes of Exercise Training) trial ran-
domly assigned 2,331 patients with HF due to systolic
dysfunction to usual care alone versus usual care plus aerobic
exercise training, and provides an opportunity to elucidate
the relation between exercise volume (EV) and clinical
outcomes. Specifically, we identified a subset of 959 patients
randomly assigned to the exercise training arm who were
event-free for at least 3 months. We tested the hypothesis
that EV has an inverse association, either linear or logarith-
mic, with the adjusted risk for subsequent clinical events.
We used a logarithmic transformation to account for skew-
ness in the EV data and adjusted the risk for important
baseline variables to control for confounding with baseline
health status. We also estimated the adjusted risk and the
change in exercise capacity associated with 5 different
categories of EV. Our primary outcome was all-cause
mortality or hospitalization, and our secondary outcomes
were the disease-specific endpoint of CV mortality or HF
hospitalization and change in exercise capacity as measured
by peak oxygen uptake (VO2).
Methods
Study design and patients. The HF-ACTION trial en-
rolled patients (left ventricular ejection fraction35%) with
New York Heart Association functional class II to IV
symptoms despite optimal therapy; the design and primary
Abbreviations
and Acronyms
CR  cardiac rehabilitation
CV  cardiovascular
EV  exercise volume
HF  heart failure
MET  metabolic
equivalent
VO2  oxygen uptakeresults have been previously reported (4,10). The protocol ewas approved by the institutional review board or ethics
committee for each center, and patients provided written
informed consent.
Exercise training protocol. All patients received an edu-
cation manual that recommended 30 min of moderate
intensity activity most days of the week (11). Patients
randomly assigned to the exercise arm were scheduled to
participate in supervised walking or stationary cycling 3 days
per week. After completing 18 sessions, patients were asked
to add a 2-day per week home-based exercise program.
They were fully transitioned to a 5-day per week home-
based exercise program after completing 36 supervised
sessions. The duration for supervised exercise was 30 min;
intensity was initially set at a heart rate of 60% of heart rate
reserve (i.e., peak heart rate  resting heart rate  0.6 
esting heart rate) (12) and titrated to 70% of heart rate re-
erve. This intensity corresponds to 70% of peak VO2
reserve (12) and is effective for improving exercise capacity
in patients with HF who are taking a beta-adrenergic
blocking agent (13). Home exercise was prescribed at 40
min at 60% to 70% of heart rate reserve. Each patient
received a heart rate monitor (Polar USA, Lake Success,
New York) to facilitate adherence. Among patients in
whom heart rate was an invalid measure of exercise intensity
(e.g., atrial fibrillation), the Borg rating of perceived exer-
tion scale was used and set at a level of 12 to 14 (i.e., fairly
light to somewhat hard).
Exercise volume. We used metabolic equivalent (MET)-h
per week to quantify EV, which is the product of exercise
intensity (where 1 MET is 3.5 ml O2 · kg
1 · min1) and
the hours of exercise per week. For example, for the patient
whose peak MET level during his or her last cardiopulmo-
nary exercise test was 5 and then exercise trained, on
average, at 60% intensity over the 3-month interval, they
would be exercising at an intensity of3 METs (14). If this
patient trained 1.5 h per week (i.e., 30 min, 3 days per
week), his or her EV would be  4.5 MET-h per week.
The MET-h per week data recorded during months 1 to
3 were derived from each supervised exercise session or, for
home-based exercise, from self-reported activity logs and
telephone follow-up calls. Telephone calls were scheduled
every 2 weeks for 9 months and then monthly through
month 24.
Exercise testing. Cardiopulmonary exercise testing was
performed before and 3 months after randomization. Pa-
tients were tested using a modified Naughton treadmill
protocol or ramp (10 W · min1) stationary cycle protocol.
uring testing, patients were encouraged to achieve a rating
f perceived exertion of 17 (very hard) on the Borg scale
nd a respiratory exchange ratio 1.10.
ndpoints. The primary outcome in this analysis was a
omposite of all-cause mortality or hospitalization. The
econdary clinical outcome was CV mortality or HF hospi-
alization. Because of the nature of the intervention, blind-
ng subjects and site investigators was not possible. How-
ver, all deaths, and other clinical endpoints to first HF
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November 6, 2012:1899–905 Exercise Volume and Heart Failurehospitalization, were adjudicated by a Clinical Endpoints
Committee. Cardiopulmonary exercise test data were for-
warded to a core laboratory for analysis. Peak VO2 was
efined as the highest VO2 for a given 15-s to 20-s interval
ithin the last 90 s of exercise or the first 30 s of recovery.
tatistics. The associations between EV, measured in
ET-h per week during months 1 to 3, and the clinical
ndpoints were assessed using the Cox proportional hazards
odel, which modeled the time to first occurrence of each
ndpoint. Only patients randomly allocated to the exercise
raining arm of HF-ACTION who did not experience the
rimary endpoint during the first 3 months were included in
his analysis (n  959) (Fig. 1). This inclusion criterion was
sed to ensure an opportunity for at least 3 months of
xercise training for patients in the current analysis. Also,
ny patient who experienced the primary endpoint during
onths 1 to 3, by definition, reached the endpoint before
he reporting of EV at 3 months. As a result, in the time to
rst event Cox model analyses, a subject’s EV could not be
sed to predict an endpoint that already occurred. Conse-
uently, the Cox analyses used 3 months after randomiza-
ion as time zero, a so-called “landmark” analysis (15).
Sixty candidate baseline variables, including the variables
onsidered for the HF-ACTION risk model (16), were
onsidered for covariate adjustment. The SAS procedure
ROC MI was used to create 5 complete data sets with
mputed values to fill in missing values among candidate
Figure 1 Study Flow Chart
Flow of patients through the trial to the 3-month event-free group. HF  heart
failure; LVEF  left ventricular ejection fraction; NYHA  New York Heart
Association.redictors. With the 5 completed data sets, the SAS
rocedure PROC MIANALYZE was used in conjunction
ith PROC PHREG, and backward variable selection was
sed to identify the adjustment variables for EV in the Cox
nalyses.
MET-h per week was first included as a linear term in the
ovariate-adjusted Cox models. Because MET-h per week
ad a skewed distribution, the hypothesis was tested using a
ogarithmic transformation [log2(MET-h per week1)] to
decrease the influence of outliers (17,18). Multivariate
likelihood ratios were used to determine if the linear Cox
model or the logarithmic transformed Cox model provided
a better model fit.
To estimate the relation between EV and clinical out-
come, we also divided the subjects into 5 categories of
MET-h per week: 0 to 1 (n  144), 1 to 3 (n  234),
3 to 5 (n  233), 5 to 7 (n  178), and 7 (n  170).
These categories were chosen so as to have a reasonable
number of subjects in each category, while retaining clinical
relevance. Using 0 to 1 MET-h per week as the reference
category, we then computed the unadjusted and adjusted
hazard ratios for the 4 remaining exercise categories.
Cumulative event rates were calculated using Kaplan-
Meier methods. Covariate adjusted relative risks were ex-
pressed as Cox model hazard ratios with 95% confidence
intervals. Change in peak VO2 was linearly regressed on EV
o assess the association between the 2 variables. Also the
edian (25th, 75th percentiles) change in peak VO2 was
omputed for each of the 5 categories of EV. Analyses were
erformed using SAS, version 8.2 (SAS Institute, Cary,
orth Carolina) and the R Design Library, version 2.9.2
The R Foundation for Statistical Computing, Vienna,
ustria). Statistical significance was set at the 2-tailed alpha
.05 level, with no adjustment for multiple comparisons. All
values are calculated on the basis of the Wald chi-square
tatistic. Discrete variables are expressed as percent and
ontinuous variables as median and interquartile range.
esults
atient characteristics and follow-up. Table 1 shows
baseline characteristics for patients included in our primary
analysis involving patients who were event-free at 3 months
after randomization. Among these patients, the median
duration of follow-up was 28.2 (18.0, 40.0 [25th, 75th
percentile]) months. Median EV at 3 months was 3.9 (1.9,
6.2) MET-h per week.
Clinical endpoints. As seen in Table 2, MET-h per week
was not a linear predictor of our primary endpoint (i.e.,
all-cause mortality or hospitalization; p  0.18). However,
MET-h per week was a significant logarithmic predictor of
all-cause mortality or hospitalization (p 0.03). The reason
for this difference can be seen in Figure 2, where the
adjusted hazard ratio, as a function of MET-h per week, is
somewhat reverse J-shaped. Specifically, when compared to
an EV of 0 to 1 MET-h per week, moderate EV of 3 to
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Exercise Volume and Heart Failure November 6, 2012:1899–9055 and 5 to 7 MET-h per week were associated with
reductions in adjusted risk that approximated 37% and 31%,
respectively. Consequently, the logarithmic model for
MET-h per week better captured the adjusted risk than did
the linear model, which was confirmed by the multivariate
likelihood ratios (226 vs. 223, respectively). It is also
important to note from Figure 2 that, whereas the adjusted
azard ratios were reverse J-shaped, the largest decrease in
he unadjusted hazard ratio occurred for EV 5 MET-h
er week.
For the disease-specific endpoint of CV mortality or HF
ospitalization, MET-h per week was both a significant
inear (p  0.001) and logarithmic (p  0.001) predictor of
ubsequent risk (Table 2). As shown in Figure 3, the
djusted risk reductions associated with the moderate EV of
to 5 MET-h per week and 5 to 7 MET-h per week
ere 64% and 67%, respectively. The greatest reductions in
nadjusted risk were, again, observed at the higher EV. For
V mortality or HF hospitalization, the logarithmic model
Selected Baseline Characteristics ofPatients Event-Fr e for t Least 3 MonthsTable 1 Selected B seline Characteristics ofPatients Event-Free for at Least 3 Months
Characteristics
Descriptive Statistic
(n  959)
Age, yrs 59 (51–67)
Female 297 (31)
Race*
Black or African American 306/943 (32)
White 589/943 (62)
Other 48/943 (5)
NYHA class*
II 626 (65)
III 323 (33)
IV 10 (1)
Ischemic etiology of heart failure 480 (50)
Ejection fraction, % 25 (20–30)
Diabetes mellitus 307 (32)
Previous myocardial infarction 390 (41)
Hypertension 591/954 (62)
Atrial fibrillation or flutter 204 (21)
Beck Depression Inventory II score 8 (5–15)
Systolic blood pressure, mm Hg 112 (100–126)
Diastolic blood pressure, mm Hg 70 (60–78)
Baseline medications
ACE inhibitor or ARB 917 (96)
Beta-blocker 904 (94)
Aldosterone receptor antagonist 431 (45)
Loop diuretic 728 (76)
Digoxin 415 (43)
Implantable cardioverter-defibrillator 396 (17)
Biventricular pacemaker 182 (19)
Cardiopulmonary exercise test
Peak oxygen uptake, ml · kg1 · min1 14.5 (11.6–17.8)
Peak respiratory exchange ratio 1.08 (1.01–1.16)
Values are median (interquartile range) or n (%). Percentages may not sum to 100 because of
rounding. *Indicates the number of patients/number of patients with nonmissing data.
ACE  angiotensin-converting enzyme; ARB  angiotensin-II receptor blocker; IQR  interquar-
tile range; NYHA  New York Heart Association.or MET-h per week better captured the adjusted risk thanid the linear model (multivariate likelihood ratios: 280 vs.
76, respectively).
Figure 4 shows the adjusted Kaplan-Meier event rate
urves for the 2 clinical endpoints, dichotomized on the
asis of EV during months 1 to 3: 4 MET-h per week or
4 MET-h per week. We chose 4 MET-h per week because
his approximated the median EV for months 1 to 3.
Covariate Adjusted* p Values for Exercise Volume(MET-h per Week) as a Linear r Logarithmic-Transformed† Pr ictor of Clinical Even s inPatients Event-Free for at L ast 3 Mont sn  959)
Table 2
Covariate Adjusted* p Values for Exercise Volume
(MET-h per Week) as a Linear or Logarithmic-
Transformed† Predictor of Clinical Events in
Patients Event-Free for at Least 3 Months
(n  959)
Clinical Event
Model for MET-h
per Week p Value
All-cause mortality or hospitalization
(582 events)
Linear 0.18
Logarithmic 0.03
Cardiovascular mortality or heart failure
hospitalization (250 events)
Linear 0.001
Logarithmic 0.001
*Adjustment variables: Weber class; sex; serum sodium (136 mEq · l1); ventricular conduction
on resting electrocardiogram before exercise test; mitral regurgitation grade; resting heart rate;
prescribed a beta-adrenergic-blocking agent; Kansas City Cardiomyopathy Questionnaire total
symptom, social limitation, and symptom stability scores; left ventricular ejection fraction; loop
diuretic dose (truncated above 90 mg · day1 furosemide equivalent); blood urea nitrogen
(truncated at 47 mg · dl1); Beck Depression Inventory II score (truncated at 8); geographic region;
peak respiratory exchange ratio on cardiopulmonary exercise test (truncated above 1.3); marital
status; employment status; and etiology of heart failure. †The logarithmic transformation was
Log2(MET-h per week  1).
MET  metabolic equivalent.
Figure 2 Hazard Ratios for
All-Cause Mortality or Hospitalization
Among patients event-free for at least 3 months, adjusted hazard ratios (solid
circles, log scale) are given for all-cause mortality or hospitalization with 95%
confidence intervals; reference category is 0 to 1 metabolic equivalent (MET)-h
per week. Unadjusted hazard ratios are plotted with open circles.
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November 6, 2012:1899–905 Exercise Volume and Heart FailureExercise capacity. There was a significant association be-
ween the EV completed by subjects during the first 3
onths of the trial and change in exercise capacity at 3
onths (r  0.10; p  0.005, n  853). The median (25th,
5th percentiles) changes in peak VO2 for patients exercis-
ing 0 to 1, 1 to 3, 3 to 5, 5 to 7, and 7 MET-h
per week were 0.4 (1.2, 1.0), 0.6 (0.7, 2.1), 0.5 (0.7,
2.4), 0.9 (0.5, 2.5), and 0.9 (0.5, 2.9) ml · kg1 · min1,
espectively.
Figure 3 Hazard Ratios for Cardiovascular Mortality
or Heart Failure Hospitalization
Among patients event-free for at least 3 months, adjusted hazard ratios (solid
circles, log scale) are given for cardiovascular mortality or heart failure hospi-
talization with 95% confidence intervals; reference category is 0 to 1 metabolic
equivalent (MET)-h per week. Unadjusted hazard ratios are plotted with open
circles.
Figure 4 Adjusted Kaplan-Meier Curves for Clinical Outcomes
Adjusted Kaplan-Meier curves for all-cause mortality or hospitalization (A) and card
least 3 months, stratified at the median exercise volume of 4 metabolic equivalen
MET-h per week.iscussion
his study provides new and important information con-
erning the association between the volume of exercise
ompleted per week and subsequent risk for clinical events
n a large cohort of stable outpatients with systolic HF. When
reated as a continuous variable, EV was not significant (p 
.18) when modeled as a linear predictor for all-cause mortality
r hospitalization, but was significant when modeled as a
ogarithmic predictor (p  0.03) because the latter better
xpressed the association between EV and the primary end-
oint. The reason for the improved fit using the logarithmic
odel was because the adjusted risk resembled a reverse
-shaped function of EV, where moderate EV of 3 to 5 and
to 7 MET-h per week were associated with reductions in
ubsequent risk that exceeded 30% (Figs. 2 and 3).
For the CV mortality or HF hospitalization endpoint,
V treated as a continuous variable was a significant
redictor regardless of whether it was modeled linearly or
ogarithmically. This is because of the greater effect that EV
ad on CV mortality or HF hospitalization (versus all-cause
ortality or hospitalization). This finding is consistent with
he main HF-ACTION trial (4), in which exercise training
ad its greatest effect on CV mortality or HF hospitalization,
uggesting a greater specificity for reducing HF-related end-
oints. Although we can only speculate as to the mechanisms
esponsible for the favorable impact of exercise training on
linical outcomes in patients with HF, especially its more
avorable effect on the HF-specific endpoint, numerous studies
how that regular exercise improves much of the pathophysi-
logy that is unique to HF, including changes in central
19,20), inflammatory (21–24), neuroendocrine (25,26), endo-
helial (19,27,28), and skeletal muscle (29,30) function.
cular mortality or heart failure hospitalization (B) in patients event-free for at
)-h per week; dotted line indicates 4 MET-h per week, solid line indicates 4iovas
t (MET
w
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Exercise Volume and Heart Failure November 6, 2012:1899–905For both clinical endpoints, we observed that an EV 7
MET-h per week was associated with a smaller decrease in
adjusted risk than both the 3 to 5 MET-h per week and
the 5 to 7 MET-h per week groups (Figs. 2 and 3). That
was because 1) peak VO2, categorized by Weber class (31),
as highly associated with clinical outcome (adjusted p 
.0001); and 2) a higher EV was associated with a higher
eak VO2. Indeed, the median peak VO2 at baseline for
our 0 to 1, 1 to 3, 3 to 5, 5 to 7, and 7 MET-h
per week categories were 13.1, 12.6, 13.4, 16.0, and
17.7 ml · kg1 · min1, respectively. Because the adjusted risk
associated with EV represents the ability of EV to indepen-
dently predict clinical outcome, we observe that EV had less
ability to independently predict clinical outcome in the 7
MET-h per week group than it did for other groups (e.g., 3
to5 MET-h per week group or 5 to7 MET-h per week
group). Nevertheless, there was a larger decrease in unad-
justed risk as EV increased because EV reflects better
baseline health, rather than the independent predictive
ability of EV.
These findings showing an association between EV
(treated as a continuous variable or across all 5 categories)
and clinical endpoints is consistent with prior observational
studies in older coronary patients that treated the amount of
exercise completed in a dichotomous manner (8,9). Ham-
mill et al. (9) observed that among Medicare beneficiaries
with HF who attended 36 versus 12 CR sessions, all-cause
mortality was reduced by approximately 18%. Combining
the observations from our study with those of prior studies
that involved exercise in patients with HF (4–7,9), it seems
reasonable to suggest that a moderate volume of exercise
training (e.g., 3 to 7 MET-h per week) is safe and associated
with a reduction in risk for important clinical endpoints.
Among all 1,159 patients randomly assigned to the
exercise group in the HF-ACTION trial, only 40%
reported exercising at or above the protocol prescribed
minimum number of minutes per week during the first 12
months (4). Therefore, this study may provide insight
regarding how the EV completed by patients participating
in the trial might have contributed to the modest improve-
ment in clinical outcomes reported in the main outcomes
paper. Clearly, maintaining an exercise program can be a
challenge for the patient with HF, a behavior that is
influenced both by pre-existing comorbidities (32) and
practitioners who often do not routinely assess a patient’s
health beliefs and self-efficacy for change (33). However,
our observation that a large decrease in adjusted risk for
both clinical endpoints occurred among patients training at
only 3 to 5 MET-h per week (Figs. 2 and 3) may be a
potentially important motivating strategy, especially when
counseling sedentary patients with HF who experience
exercise intolerance and are reluctant to exercise. For refer-
ence, 4 MET-h per week approximates walking at just 1.7
miles per hour for 26 min, 4 times per week.
The EV completed by patients during the first 3 months
of the trial was significantly associated with the change inpeak VO2 measured at 3 months. Across all 5 categories of
EV, the median increases in exercise capacity were modest
and below the 1 to 4 ml · kg1 · min1 increases reported for
atients with HF taking evidence-based therapy (13). How-
ver, among patients exercise training at 5 MET-h per
eek, the median increase in peak VO2 was 0.9
ml · kg1 · min1, a value that approaches what is often
considered a clinically meaningful change (i.e., 6% or 1
ml · kg1 · min1) (34,35). Initial reports (36,37) involving
patients with HF suggest that higher intensity interval
training may be an alternate method to attain a higher
volume of exercise, with the potential to yield a greater
improvement in peak VO2.
Study limitations. Despite the large sample size, the rig-
orous collection of EV and clinical event data, and the blind
adjudication of endpoints, there are potential limitations
associated with this study. First, it is possible that selection
bias, such as those patients who expressed interest in
exercise, were healthier, or adhered better to medical treat-
ment plans, might have been more physically able and likely
to undertake the exercise regimen. Nevertheless, the asso-
ciation between EV and clinical events persisted after
adjusting for major variables associated with clinical status.
A sufficiently powered prospective trial that randomly as-
signed subjects to different EV is warranted to establish a
causal relationship.
Second, although this study was a planned secondary anal-
ysis in the HF-ACTION protocol, it is a retrospective analysis
of prospectively collected data. Therefore, some of the associ-
ations we observed between EV and outcome may be partly
due to the presence or absence of other factors that indepen-
dently affect clinical events. Although we controlled for the
influence of many of these potentially confounding variables,
our models still may not have included variables that are also
related to adherence to exercise or the clinical endpoints.
Third, because missing data for some of the clinical
variables measured at baseline, we used multiple imputation
as a means to include a greater number of candidate
variables when conducting the multivariable analyses. It is
unknown whether multiple imputation influenced bias,
versus simply omitting variables with incomplete data,
although the imputation methods we employed have been
shown to reduce bias in many situations (38).
Conclusions
Among patients with chronic systolic HF on evidence-
based therapy, our results extend the findings from the main
HF-ACTION trial by estimating the adjusted hazard ratios
(i.e., independent risk reductions) associated with various
levels of EV completed during the first 3 months after
randomization. We found that the adjusted hazard ratio as
a function of EV was reverse J-shaped, and because of this
association, EV was not a significant linear predictor for
all-cause mortality or hospitalization but was significant as a
logarithmic predictor. For CV mortality or HF hospitaliza-
1905JACC Vol. 60, No. 19, 2012 Keteyian et al.
November 6, 2012:1899–905 Exercise Volume and Heart Failuretion, EV was a significant linear predictor and logarithmic
predictor. Moderate EV between 3 and 7 MET-h per week
were associated with reductions in adjusted risk that ex-
ceeded 30%. Although further study is warranted to confirm
the relations between EV and clinical outcomes, our find-
ings support the use of moderate, regular exercise in the
management of patients with chronic systolic HF.
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Department of Cardiovascular Medicine, Henry Ford Hospital,
6525 Second Avenue, Detroit, Michigan 48202. E-mail:
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